Clinical trial · Interventional
Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy
NCT02281487CI-TRIAL-00027813HYSTUBcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether a tubectomy during hysterectomy for benign gynaecological conditions does not result into a premature menopause.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Hysterectomy (& Wertheim) | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hysterectomy | Procedure | — | UNRESOLVED |
| Hysterectomy plus Tubectomy | Procedure | — | UNRESOLVED |
| light microscopy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Hysterectomy
- description
- standard hysterectomy
- interventionNames
- Procedure: Hysterectomy
- type
- EXPERIMENTAL
- label
- Hysterectomy plus tubectomy
- description
- Hysterectomy plus tubectomy
- interventionNames
- Procedure: Hysterectomy plus Tubectomy
- Device: light microscopy
Primary outcomes (1)
- measure
- Anti Mullerian Hormone
- timeFrame
- at baseline and on average six months after the operation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 36 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * hysterectomy (abdominally or laparoscopically) for benign indications * premenopausal * age \>36 \< 55 Exclusion Criteria: * history of cancer * hereditary cancer in the family * previous intraluminal tubal occlusion * previous salpingitis * failure to perform a tubectomy during hysterectomy
References
Publications (5)
- BACKGROUNDPiek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH. Tubal ligation and risk of ovarian cancer. Lancet. 2001 Sep 8;358(9284):844. doi: 10.1016/S0140-6736(01)05992-X. No abstract available. PMID 11570411
- BACKGROUNDKurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79. PMID 20154587
- BACKGROUNDCrum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009 Apr;3(2):165-70. doi: 10.1016/j.molonc.2009.01.004. Epub 2009 Feb 3. PMID 19383378
- BACKGROUNDSezik M, Ozkaya O, Demir F, Sezik HT, Kaya H. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow. J Obstet Gynaecol Res. 2007 Dec;33(6):863-9. doi: 10.1111/j.1447-0756.2007.00669.x. PMID 18001455
- BACKGROUNDNarod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001 May 12;357(9267):1467-70. doi: 10.1016/s0140-6736(00)04642-0. PMID 11377596